These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10750777)

  • 1. Molecular biologic substaging of stage I lung cancer according to gender and histology.
    D'Amico TA; Aloia TA; Moore MB; Herndon JE; Brooks KR; Lau CL; Harpole DH
    Ann Thorac Surg; 2000 Mar; 69(3):882-6. PubMed ID: 10750777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers.
    D'Amico TA; Massey M; Herndon JE; Moore MB; Harpole DH
    J Thorac Cardiovasc Surg; 1999 Apr; 117(4):736-43. PubMed ID: 10096969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer.
    Harpole DH; Richards WG; Herndon JE; Sugarbaker DJ
    Ann Thorac Surg; 1996 May; 61(5):1470-6. PubMed ID: 8633961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery.
    Carbognani P; Tincani G; Crafa P; Sansebastiano G; Pazzini L; Zoni R; Bobbio A; Rusca M
    J Cardiovasc Surg (Torino); 2002 Aug; 43(4):545-8. PubMed ID: 12124571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.
    Kwiatkowski DJ; Harpole DH; Godleski J; Herndon JE; Shieh DB; Richards W; Blanco R; Xu HJ; Strauss GM; Sugarbaker DJ
    J Clin Oncol; 1998 Jul; 16(7):2468-77. PubMed ID: 9667266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study.
    Ahrendt SA; Hu Y; Buta M; McDermott MP; Benoit N; Yang SC; Wu L; Sidransky D
    J Natl Cancer Inst; 2003 Jul; 95(13):961-70. PubMed ID: 12837832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
    Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G
    J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma.
    Xu HJ; Quinlan DC; Davidson AG; Hu SX; Summers CL; Li J; Benedict WF
    J Natl Cancer Inst; 1994 May; 86(9):695-9. PubMed ID: 8158700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.
    Harpole DH; Marks JR; Richards WG; Herndon JE; Sugarbaker DJ
    Clin Cancer Res; 1995 Jun; 1(6):659-64. PubMed ID: 9816029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer.
    Chansky K; Sculier JP; Crowley JJ; Giroux D; Van Meerbeeck J; Goldstraw P;
    J Thorac Oncol; 2009 Jul; 4(7):792-801. PubMed ID: 19458556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer.
    Miao S; Qiu T; Zhao Y; Wang H; Sun X; Wang Y; Xuan Y; Qin Y; Jiao W
    Thorac Cancer; 2018 Sep; 9(9):1136-1144. PubMed ID: 30047626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study.
    Sakurai H; Asamura H; Goya T; Eguchi K; Nakanishi Y; Sawabata N; Okumura M; Miyaoka E; Fujii Y;
    J Thorac Oncol; 2010 Oct; 5(10):1594-601. PubMed ID: 20736855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do molecular markers predict survival in non-small-cell lung cancer?
    Greatens TM; Niehans GA; Rubins JB; Jessurun J; Kratzke RA; Maddaus MA; Niewoehner DE
    Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1093-7. PubMed ID: 9563724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression.
    Ohsaki Y; Tanno S; Fujita Y; Toyoshima E; Fujiuchi S; Nishigaki Y; Ishida S; Nagase A; Miyokawa N; Hirata S; Kikuchi K
    Oncol Rep; 2000; 7(3):603-7. PubMed ID: 10767376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.